Related Experiment Videos
Demonstration of plasma proteinase inhibitors in beta 2-microglobulin amyloid deposits
J M Campistol1, T Shirahama, C R Abraham
1Arthritis Center, Boston University School of Medicine, Massachusetts.
Abstract:
beta 2-microglobulin-related amyloidosis (A beta 2M) represents a frequent complication in long-term dialysis patients. Although the pathogenetic mechanism has yet to be fully understood, it is known that amyloid fibrils usually consist of intact molecules of beta 2-microglobulin (beta 2m). Plasma proteinase inhibitors (PPI) are a broad family of glycoproteins with the function of eliminating unwanted proteolysis of serine proteases. Their role in amyloidogenesis has become a subject of intense discussion, especially since the recent identification of alpha 1-antichymotrypsin in the beta-protein amyloid deposits of Alzheimer's disease. We evaluated immunohistochemically and biochemically the presence and distribution of several PPIs (alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-macroglobulin and tissue inhibitor metalloproteinase) and amyloid P component in A beta 2M deposits in osteo-articular and visceral tissues from dialysis patients with amyloidosis, as well as two carpal tunnel synovia from non-dialysis patients and one Alzheimer's brain as controls. The immunohistochemical study demonstrated that all but one (anti-alpha 1-antichymotrypsin) of the PPI antibodies tested showed varying degrees of positive reaction against A beta 2M deposits. All the antibodies (including anti-alpha 1-antichymotrypsin) also reacted to some extent with other non-amyloid visceral and connective tissue elements diffusely and/or selectively. Among them, only the reaction of anti-amyloid P component had significantly distinctive localization to A beta 2M deposits, which were identified in adjacent serial sections by Congo red staining and immunohistochemical reaction against anti-beta 2m.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Beta 2-microglobulin amyloidosis (A beta 2M) is common in dialysis patients. This study investigates plasma proteinase inhibitors in A beta 2M deposits, finding amyloid P component is a specific marker.
Area of Science:
- Nephrology
- Biochemistry
- Pathology
Background:
- Beta 2-microglobulin amyloidosis (A beta 2M) is a frequent complication in patients undergoing long-term dialysis.
- Amyloid fibrils in A beta 2M are primarily composed of intact beta 2-microglobulin (beta 2m).
- The role of plasma proteinase inhibitors (PPIs) in amyloidogenesis is under investigation, particularly after their presence in Alzheimer's disease amyloid deposits.
Purpose of the Study:
- To evaluate the presence and distribution of various PPIs and amyloid P component in A beta 2M deposits.
- To compare A beta 2M tissues with control tissues from non-dialysis patients and Alzheimer's disease.
Main Methods:
- Immunohistochemical and biochemical analysis of osteo-articular and visceral tissues.
- Testing antibodies against alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-macroglobulin, tissue inhibitor metalloproteinase, and amyloid P component.
- Control tissues included carpal tunnel synovia and Alzheimer's brain.
Main Results:
- Most PPI antibodies showed positive reactions with A beta 2M deposits, though not exclusively.
- Antibodies against alpha 1-antichymotrypsin reacted less strongly with A beta 2M deposits compared to other PPIs.
- Only anti-amyloid P component antibody demonstrated significantly specific localization to A beta 2M deposits.
Conclusions:
- Amyloid P component is a highly specific marker for A beta 2M deposits.
- The role of PPIs in the pathogenesis of A beta 2M requires further investigation.
- Immunohistochemistry is a valuable tool for characterizing amyloid deposits.